Search results for " THROMBOSIS"

showing 10 items of 328 documents

Long Term Results After Repair of Type A Acute Aortic Dissection According to False Lumen Patency.

2009

Background. Late survival and freedom from retreatment on the descending aorta was evaluated after ascending aortic repair for type A acute aortic dissection (TAAAD). Methods. Between March 1992 and January 2006, 189 TAAAD patients (mean age, 52 11; range, 17 to 83 years) were included; of these, 58 had a patent false lumen, and 49 had Marfan syndrome. The descending aorta was evaluated postoperatively with computed tomography (CT). Late outcomes were assessed by Cox regression analysis and actuarial survival and freedom from retreatment by the Kaplan-Meier method. Mean follow-up was 88 44 months. Results. There were 38 (20%) late deaths. At 10 years, survival was 89.8% 2.1% for patients wi…

False Lumen PatencySettore MED/23 - Chirurgia CardiacaFollow-up False lumen thrombosis aortic dissection
researchProduct

Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results fro…

2019

Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, potentially fatal disorder of haematopoietic stem cells caused by mutations in an X-linked gene called phosphatidylinositol glycan class A, characterised by intravascular haemolysis, bone marrow failure and thrombotic events. The disease can occur at any age, although preferentially it affects young adults; its estimated prevalence is about 1/500,000 [1]. Clinical symptoms are variable and can include haemolytic anaemia, moderate to severe impairment of haematopoiesis and, in approximately 40% of patients, thrombosis of the vessels of the abdomen, brain and skin [2]. Rare, atypical site thrombosis of the splanchnic veins or cerebral sinu…

First episodemedicine.medical_specialtybusiness.industryCross-sectional studyHemoglobinuria ParoxysmalThrombosisHematologymedicine.diseasePhenotypePeripheralVein thrombosisVenous thrombosisCross-Sectional StudiesPhenotypeInternal medicinemedicineCardiologyHumansParoxysmal nocturnal haemoglobinuriaRisk factorbusinessCerebral sinus venous thrombosisPNHRisk factorScreeningVenous thrombosis
researchProduct

Residual Vein Thrombosis Improves Screening for Occult Cancer: Results On 537 Patients with Idiopathic Deep Vein Thrombosis

2009

Abstract Abstract 3999 Poster Board III-935 Background Clinical advantage of extensive screening for occult cancer in patients with idiopathic Deep Vein Thrombosis (DVT) is unknown. We have demonstrated that the Residual Vein Thrombosis (RVT)-based screening for occult cancer improves early detection as well as cancer-related mortality (Siragusa S et al. Blood 2007;110(699):OC). Here we report on final analysis of 537 patients over a period of 8 years. Objective of the study We conducted a prospective study evaluating whether a RVT-based screening for cancer is sensitive and influences cancer-related mortality. Study design Prospective with two cohorts of DVT patients: the first cohort was …

First episodemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryDeep veinImmunologyCancerColonoscopyCell BiologyHematologymedicine.diseaseBiochemistryOccultSurgerycancer residual vein thrombosisSettore MED/15 - Malattie Del Sanguemedicine.anatomical_structureInternal medicineCohortCancer screeningmedicineProspective cohort studybusiness
researchProduct

Cancer-Related Venous Thrombosis: Residual Vein Thrombosis Improves Screening for Occult Cancer.

2007

Abstract Background. Clinical advantages of extensive screening for occult cancer in patients with idiopathic Deep Vein Thrombosis (DVT) is still debated since this approach improves early detection of cancer but not cancer-related mortality. Recently, we have demonstrated that patients with Residual Vein Thrombosis (RVT), 3 months after DVT, have a high risk for cancer in the subsequent 2 years (Siragusa S et al. Blood2005;106(11):OC262). At the present it is unknown whether RVT assessment may be used to select patients, with idiopathic DVT, who require screening for occult cancer. Objective of the study. We conducted a prospective study evaluating whether a RVT-based screening for cancer …

First episodemedicine.medical_specialtymedicine.diagnostic_testbusiness.industryDeep veinImmunologyCancerColonoscopySigmoidoscopyCell BiologyHematologymedicine.diseaseBiochemistrySurgeryVenous thrombosismedicine.anatomical_structureInternal medicineCohortmedicinebusinessProspective cohort studyBlood
researchProduct

Testing for goodness rather than lack of fit of an X–chromosomal SNP to the Hardy-Weinberg model

2019

The problem of checking the genotype distribution obtained for some diallelic marker for compatibility with the Hardy-Weinberg equilibrium (HWE) condition arises also for loci on the X chromosome. The possible genotypes depend on the sex of the individual in this case: for females, the genotype distribution is trinomial, as in the case of an autosomal locus, whereas a binomial proportion is observed for males. Like in genetic association studies with autosomal SNPs, interest is typically in establishing approximate compatibility of the observed genotype frequencies with HWE. This requires to replace traditional methods tailored for detecting lack of fit to the model with an equivalence test…

HeredityNormal DistributionDistance MeasurementTrinomial01 natural sciencesLinkage Disequilibrium010104 statistics & probabilityStatisticsLack-of-fit sum of squaresMathematicsVenous ThrombosisMeasurement0303 health sciencesMultidisciplinaryQRSoftware EngineeringGenomicsHardy–Weinberg principleGenetic MappingPhysical SciencesEngineering and TechnologyMedicineResearch ArticleComputer and Information SciencesScienceGeometryAsymptotic distributionVariant GenotypesPolymorphism Single NucleotideMolecular Genetics03 medical and health sciencesGenome-Wide Association StudiesGeneticsTest statisticHumansComputer Simulation0101 mathematicsMolecular BiologyGenetic Association Studies030304 developmental biologyChromosomes Human XModels StatisticalModels GeneticSoftware ToolsBiology and Life SciencesComputational BiologyHuman GeneticsGenome AnalysisProbability TheoryProbability DistributionGenotype frequencyRadiiSample size determinationSample SizeBinomial proportion confidence intervalMathematicsPLOS ONE
researchProduct

CD248 enhances tissue factor procoagulant function, promoting arterial and venous thrombosis in mouse models

2021

BACKGROUND: CD248 is a pro-inflammatory, transmembrane glycoprotein expressed by vascular smooth muscle cells (VSMC), monocytes/macrophages, and other cells of mesenchymal origin. Its distribution and properties are reminiscent of those of the initiator of coagulation, tissue factor (TF). OBJECTIVE: We examined whether CD248 also participates in thrombosis. METHODS: We evaluated the role of CD248 in coagulation using mouse models of vascular injury, and by assessing its functional interaction with the TF-factor VIIa (FVIIa)-factor X (FX) complex. RESULTS: The time to ferric chloride-induced occlusion of the carotid artery in CD248 knockout (KO) mice was significantly longer than in wild-typ…

InflammationFactor VIIa030204 cardiovascular system & hematologyInferior vena cavaArticleThromboplastin03 medical and health sciencesTissue factorchemistry.chemical_compoundMice0302 clinical medicineThrombinTissue factor pathway inhibitorAntigens CDAntigens NeoplasmmedicineAnimalsHumansMice KnockoutVenous Thrombosismedicine.diagnostic_testFactor XHematologyCoagulationchemistrymedicine.veinCancer researchProthrombin Timemedicine.symptommedicine.drugPartial thromboplastin time
researchProduct

Unexpected role of natural killer cell-derived interferon-γ as a driver of NETosis and DVT.

2018

Killer Cells NaturalVenous ThrombosisInterferon-gammamedicine.anatomical_structureInterferon γChemistrymedicineCancer researchHumansHematologyExtracellular TrapsNatural killer cellJournal of thrombosis and haemostasis : JTH
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference.

2016

Abstract Patients with cirrhosis present with hemostatic alterations secondary to reduced availability of pro-coagulant and anti-coagulant factors. The net effect of these changes is a rebalanced hemostatic system. The Italian Association of the Study of the Liver (AISF) and the Italian Society of Internal Medicine (SIMI) promoted a consensus conference on the hemostatic balance in patients with cirrhosis. The consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Rome in December 2014. The statements were graded according to quality of evidence and strength of recommendations, and approved by an independent …

Liver CirrhosisCirrhosisBleeding; Cirrhosis; Hemostasis; Thrombosis; Hepatology; GastroenterologySettore MED/09 - Medicina InternaBleeding; Cirrhosis; Hemostasis; Thrombosis; Anticoagulants; Coagulants; Drug Monitoring; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Postoperative Hemorrhage; Thrombosis; Blood Coagulation Tests; Hemostasis; Hepatology; Gastroenterology0302 clinical medicineEsophageal and Gastric VariceBlood coagulation testConsensus conferenceGastroenterologyThrombosisOptimal managementCirrhosisCoagulant030220 oncology & carcinogenesisThrombosi030211 gastroenterology & hepatologyBlood Coagulation TestsDrug MonitoringGastrointestinal HemorrhageHumanmedicine.medical_specialtyLiver CirrhosiBleeding; Cirrhosis; Hemostasis; Thrombosis; Gastroenterology; HepatologyPostoperative HemorrhageEsophageal and Gastric VaricesNO03 medical and health sciencesInternal medicinemedicineHumansIn patientIntensive care medicineHemostasisCirrhosiHepatologybusiness.industryCoagulantsBleeding; Cirrhosis; Hemostasis; ThrombosisBleedingAnticoagulantAnticoagulantsThrombosisHepatologyHemostasiBlood Coagulation Testmedicine.diseaseSurgeryHemostasisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Thrombophilic genetic factors PAI-1 4G-4G and MTHFR 677TT as risk factors of alcohol, cryptogenic liver cirrhosis and portal vein thrombosis, in a Ca…

2015

The thrombophilic genetic factors (THRGFs), PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q and Prothrombin 20210A, were studied as risk factors in 865 Caucasian patients with liver cirrhosis, consecutively enrolled from June 2008 to January 2014. A total of 582 HCV, 80 HBV, 94 alcohol, (82 with more than one etiologic factor) and 191 cryptogenic patients with liver cirrhosis had been consecutively enrolled; 243 patients showed portal vein thrombosis (PVT). At least one of the above THRGFs was present in 339/865 patients (39.2%). PAI-1 4G-4G and MTHFR 677TT were the most frequent THRGFs, statistically significant in patients with alcohol, cryptogenic liver cirrhosis, and PVT: respectively 24 and 28…

Liver CirrhosisMalemedicine.medical_specialtyAlcoholic liver diseaseCirrhosisAlcohol DrinkingAlcoholThrombophiliaLogistic regressionGastroenterologyPolymorphism Single NucleotideWhite Peoplechemistry.chemical_compoundRisk FactorsInternal medicineGenotypePlasminogen Activator Inhibitor 1GeneticsmedicineHumansGenetic Predisposition to DiseaseGenetic Association StudiesMethylenetetrahydrofolate Reductase (NADPH2)Venous ThrombosisbiologyPortal VeinGeneral Medicinemedicine.diseasedigestive system diseasesPortal vein thrombosischemistryMethylenetetrahydrofolate reductasebiology.proteinFemaleGene
researchProduct